(PGNX) |
| 0 (0%) 07-18 19:45 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 10.96 |
| Resistance 1: | 10.88 |
| Pivot price: | 10.86 |
| Support 1: | 10.76 |
| Support 2: | 8.95 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Thu, 07 May 2020
Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update - GlobeNewswire
Thu, 07 Nov 2019
Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results - GlobeNewswire
Thu, 25 Jul 2019
Progenics Pharmaceuticals Announces Collaboration with - GlobeNewswire
Tue, 06 Dec 2016
Why Progenics Pharmaceuticals, Inc. Stock Climbed 76.5% in November - The Motley Fool
Wed, 20 Jul 2016
Valeant wins FDA oral Relistor approval and $1B sales potential - Fierce Biotech
Tue, 22 Jan 2013
Progenics Acquires Molecular Insight Pharmaceuticals to Expand Oncology-Focused Pipeline - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
